Avenue Therapeutics, Inc. ATXI
We take great care to ensure that the data presented and summarized in this overview for AVENUE THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ATXI
Top Purchases
Top Sells
About ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Insider Transactions at ATXI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 16
2024
|
Fortress Biotech, Inc. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
413,507
+10.44%
|
-
|
|
Jan 02
2024
|
Fortress Biotech, Inc. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
2,101,496
+40.14%
|
-
|
|
Dec 11
2023
|
Robert L Davidow > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
353,000
-38.72%
|
$0
$0.14 P/Share
|
|
Dec 11
2023
|
Robert L Davidow > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
264,000
-27.94%
|
$0
$0.14 P/Share
|
|
Sep 08
2023
|
Fortress Biotech, Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
418,410
+28.84%
|
$0
$0.72 P/Share
|
|
Sep 08
2023
|
Lindsay A Md Rosenwald Director |
BUY
Open market or private purchase
|
Direct |
348,675
+49.6%
|
$0
$0.72 P/Share
|
|
Mar 31
2023
|
Fortress Biotech, Inc. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
52,419
+7.87%
|
-
|
|
Jan 03
2023
|
Fortress Biotech, Inc. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
231,316
+29.17%
|
-
|
|
Dec 31
2022
|
Fortress Biotech, Inc. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
90,909
+21.59%
|
-
|
|
Oct 11
2022
|
Inva Gen Pharmaceuticals, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
388,888
-100.0%
|
$2,722,216
$7.71 P/Share
|
|
Dec 17
2021
|
Curtis Gale Oltmans Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,020
+50.0%
|
-
|
|
Dec 17
2021
|
Neil Herskowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
69,020
+16.43%
|
-
|
|
Dec 17
2021
|
Jay D Kranzler Director |
BUY
Grant, award, or other acquisition
|
Direct |
69,020
+21.57%
|
-
|
|
Dec 17
2021
|
Joseph Walter Vazzano Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,505
+37.75%
|
-
|
|
Dec 17
2021
|
Lu Lucy President, CEO |
BUY
Grant, award, or other acquisition
|
Direct |
411,616
+35.47%
|
-
|
|
Sep 15
2021
|
Joseph Walter Vazzano Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,160
-9.89%
|
$7,160
$1.62 P/Share
|
|
May 06
2021
|
Neil Herskowitz Director |
BUY
Open market or private purchase
|
Direct |
2,500
+1.82%
|
$7,500
$3.99 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 767K shares |
|---|---|
| Grant, award, or other acquisition | 2.52M shares |
| Open market or private sale | 617K shares |
|---|